adding venetoclax to ibrutinib for cll patients with high-risk disease - dr. bill wierda ash 2021
Published 10 months ago • 163 plays • Length 7:20Download video MP4
Download video MP3
Similar videos
-
6:39
ibrutinib venetoclax for chronic lymphocytic leukemia (cll) treatment - dr. bill wierda ash 2022
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
1:16
dr. wierda on ibrutinib plus venetoclax in cll
-
9:32
oral treatments for patients with chronic lymphocytic leukemia (cll) - dr. bill wierda ash 2021
-
3:02
combined ibrutinib and venetoclax in patients with treatment-naïve high-risk cll
-
1:07
ibrutinib plus venetoclax as a treatment option for cll
-
8:11
treating cll with ibrutinib combined with venetoclax after prior disease progression - ash 2021
-
1:53
achieving undetectable mrd with ibrutinib plus venetoclax for cll
-
6:14
ibrutinib plus venetoclax for treatment of cll (chronic lymphocytic leukemia) - asco 2022
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
8:11
ibrutinib combined with venetoclax for cll treatment - 4-year follow-up
-
1:03
zanubrutinib plus venetoclax for patients with cll
-
3:01
ibrutinib venetoclax for cll
-
1:33
dr. zelenetz on treatment for patients with cll who fail on ibrutinib or idelalisib
-
2:28
william wierda | ibrutinib and venetoclax combination for first-line cll: captivate phase ii trial
-
1:47
ash cll highlights: ibrutinib-venetoclax combination & undetectable mrd in ighv-mutated patients
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
8:42
how ighv mutation of cll affects response to ibrutinib venetoclax - dr. talha munir ash 2022
-
1:23
captivate: fixed-duration ibrutinib plus venetoclax in patients with cll/sll